focus -WSS

focus

author：fashion 2025-09-27 12:23:14 - browse：26264

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Free Covid tests will again be offered to all U.S. households

knowledge

WSS

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Neurocrine congenital adrenal hyperplasia trial succeeds

The problem with charging patients to message their doctors

'A game

UnitedHealth quietly bought dozens of outpatient centers

How to bring more disabled researchers into academia

entertainment

focus

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Fed up with FDA, ALS advocates consider a take

Moonlake's readout produced a cash windfall. Risks remain

Senate bill would ban some hospital facility fees

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth quietly bought dozens of outpatient centers

Bright Health sells Medicare Advantage business to Molina

IVF, abortion rights issues kick off Biden’s State of the Union

hotspot

In his State of the Union, Biden takes clear aim at 'Big Pharma'

People with substance use disorder deserve online privacy

With psoriasis trial ahead, Alumis raises $259 million

Information blocking fines are now fair game in health care

White House Covid adviser calls on docs to combat misinformation

Why the quest to eradicate polio has stumbled

focus

knowledge

knowledge

explore